Drugs / HS-001 CS
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07347197 | Jan 2026 → Jan 2028 expected | dilated cardiomyopathy, heart failure, ischemic disease | Heartseed Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04945018 | Apr 2022 → Jul 2025 overdue | heart failure, ischemic disease | Heartseed Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-001 CS | “Human (allogeneic) iPS-cell-derived cardiomyocyte spheroids (HS-001CS) transplantation with endocardial delivery systems” NCT07347197 ↗2“endocardial delivery of HS-001 CS into severe heart failure patients with reduced ejection fraction” NCT07347197 ↗ |
| Modality | Cell therapy | “Human (allogeneic) iPS-cell-derived cardiomyocyte spheroids suspension” NCT04945018 ↗ |
| Route | Other | “After screening period is completed, subjects undergo HS-001 CS transplantation.” NCT04945018 ↗ |